Holtzman L, Moskovitz M, Urban D, Nechushtan H, et al. dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score >/=50. Clin Lung Cancer 2022;23:122-134.
PMID: 35034862